NO981522L - Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister - Google Patents
Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonisterInfo
- Publication number
- NO981522L NO981522L NO981522A NO981522A NO981522L NO 981522 L NO981522 L NO 981522L NO 981522 A NO981522 A NO 981522A NO 981522 A NO981522 A NO 981522A NO 981522 L NO981522 L NO 981522L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- amino acid
- acid derivatives
- endothelin antagonists
- endothelin
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19536891A DE19536891A1 (de) | 1995-10-04 | 1995-10-04 | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
| PCT/EP1996/004205 WO1997012878A1 (de) | 1995-10-04 | 1996-09-26 | Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981522L true NO981522L (no) | 1998-04-03 |
| NO981522D0 NO981522D0 (no) | 1998-04-03 |
| NO311025B1 NO311025B1 (no) | 2001-10-01 |
Family
ID=7773950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981522A NO311025B1 (no) | 1995-10-04 | 1998-04-03 | Aminosyrederivater, legemiddel inneholdende dem og anvendelse som endotelinantagonister |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6440975B1 (no) |
| EP (1) | EP0874829A1 (no) |
| JP (1) | JP2000500738A (no) |
| KR (1) | KR19990063998A (no) |
| CN (1) | CN1202890A (no) |
| AU (1) | AU713763B2 (no) |
| BG (1) | BG63389B1 (no) |
| BR (1) | BR9610821A (no) |
| CA (1) | CA2231500A1 (no) |
| CO (1) | CO4770961A1 (no) |
| CZ (1) | CZ104598A3 (no) |
| DE (1) | DE19536891A1 (no) |
| HR (1) | HRP960437A2 (no) |
| HU (1) | HUP9900085A3 (no) |
| IL (1) | IL123611A (no) |
| MX (1) | MX9801987A (no) |
| MY (1) | MY115211A (no) |
| NO (1) | NO311025B1 (no) |
| NZ (1) | NZ319595A (no) |
| PL (1) | PL326081A1 (no) |
| SK (1) | SK43098A3 (no) |
| TR (1) | TR199800623T2 (no) |
| WO (1) | WO1997012878A1 (no) |
| ZA (1) | ZA968304B (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
| IL133800A0 (en) | 1997-07-03 | 2001-04-30 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| PL350050A1 (en) * | 1999-01-22 | 2002-10-21 | Elan Pharm Inc | Acyl derivatives which treat vla-4 related disorders |
| PE20020665A1 (es) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| AU2002239508B9 (en) | 2000-12-07 | 2005-09-08 | Gilead Palo Alto, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| JP2007520558A (ja) * | 2004-02-04 | 2007-07-26 | スミスクライン・ビーチャム・コーポレイション | キナーゼ阻害剤として有用なピリミジノン化合物 |
| KR20080059268A (ko) | 2005-09-29 | 2008-06-26 | 엘란 파마슈티칼스, 인크. | Vla-4에 의해 매개되는 백혈구 부착을 억제하는피리미디닐 아미드 화합물 |
| ATE502031T1 (de) | 2005-09-29 | 2011-04-15 | Elan Pharm Inc | Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren |
| TWI389904B (zh) | 2006-02-27 | 2013-03-21 | Elan Pharm Inc | 抑制由vla-4所調節的白血球黏附之嘧啶磺醯胺化合物 |
| CN1908183B (zh) * | 2006-08-16 | 2010-09-29 | 上海奥利实业有限公司 | 具内皮素拮抗作用的天然蛋白的酶解混合肽 |
| AU2010232642A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-piperidine compounds |
| EP2424841A1 (en) | 2009-04-27 | 2012-03-07 | Elan Pharmaceuticals Inc. | Pyridinone antagonists of alpha-4 integrins |
| NZ729137A (en) | 2014-08-04 | 2022-07-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| JP7746259B2 (ja) | 2019-12-20 | 2025-09-30 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性の化合物 |
| JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブNuevolution A/S | 核内受容体に対して活性の化合物 |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4092150A (en) * | 1976-08-27 | 1978-05-30 | Fmc Corporation | Herbicidal 5-pyrimidinecarbonitriles |
| DE68914197T2 (de) * | 1988-06-20 | 1994-11-10 | Ihara Chemical Ind Co | Alkansäurederivate und herbizide Mittel. |
| CA2053603A1 (en) | 1990-10-19 | 1992-04-20 | Katsumasa Harada | 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same |
| DE4105518A1 (de) | 1991-02-22 | 1992-08-27 | Basf Ag | Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung |
| EP0517215B1 (en) * | 1991-06-07 | 1998-09-02 | Ube Industries, Ltd. | Pyrimidine or triazine derivative, process for preparing the same and herbicide using the same |
| DE4411225A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| US5958934A (en) * | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
-
1995
- 1995-10-04 DE DE19536891A patent/DE19536891A1/de not_active Withdrawn
-
1996
- 1996-09-26 HU HU9900085A patent/HUP9900085A3/hu unknown
- 1996-09-26 US US09/051,020 patent/US6440975B1/en not_active Expired - Lifetime
- 1996-09-26 HR HR19536891.6A patent/HRP960437A2/hr not_active Application Discontinuation
- 1996-09-26 KR KR1019980702475A patent/KR19990063998A/ko not_active Ceased
- 1996-09-26 PL PL96326081A patent/PL326081A1/xx unknown
- 1996-09-26 BR BR9610821A patent/BR9610821A/pt not_active Application Discontinuation
- 1996-09-26 AU AU72147/96A patent/AU713763B2/en not_active Ceased
- 1996-09-26 CN CN96198556A patent/CN1202890A/zh active Pending
- 1996-09-26 SK SK430-98A patent/SK43098A3/sk unknown
- 1996-09-26 EP EP96933398A patent/EP0874829A1/de not_active Withdrawn
- 1996-09-26 CA CA002231500A patent/CA2231500A1/en not_active Abandoned
- 1996-09-26 TR TR1998/00623T patent/TR199800623T2/xx unknown
- 1996-09-26 JP JP9513946A patent/JP2000500738A/ja not_active Abandoned
- 1996-09-26 NZ NZ319595A patent/NZ319595A/en unknown
- 1996-09-26 CZ CZ981045A patent/CZ104598A3/cs unknown
- 1996-09-26 IL IL12361196A patent/IL123611A/xx not_active IP Right Cessation
- 1996-09-26 WO PCT/EP1996/004205 patent/WO1997012878A1/de not_active Ceased
- 1996-09-27 MY MYPI96004014A patent/MY115211A/en unknown
- 1996-10-03 ZA ZA9608304A patent/ZA968304B/xx unknown
- 1996-10-03 CO CO96052652A patent/CO4770961A1/es unknown
-
1998
- 1998-03-13 MX MX9801987A patent/MX9801987A/es not_active IP Right Cessation
- 1998-04-01 BG BG102362A patent/BG63389B1/bg unknown
- 1998-04-03 NO NO19981522A patent/NO311025B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TR199800623T2 (xx) | 1998-07-21 |
| BG102362A (en) | 1999-08-31 |
| HUP9900085A3 (en) | 2001-11-28 |
| CN1202890A (zh) | 1998-12-23 |
| AU713763B2 (en) | 1999-12-09 |
| KR19990063998A (ko) | 1999-07-26 |
| BG63389B1 (bg) | 2001-12-29 |
| CZ104598A3 (cs) | 1998-09-16 |
| US6440975B1 (en) | 2002-08-27 |
| IL123611A0 (en) | 1998-10-30 |
| ZA968304B (en) | 1998-04-03 |
| NO311025B1 (no) | 2001-10-01 |
| PL326081A1 (en) | 1998-08-17 |
| IL123611A (en) | 2001-08-26 |
| HRP960437A2 (en) | 1998-04-30 |
| WO1997012878A1 (de) | 1997-04-10 |
| JP2000500738A (ja) | 2000-01-25 |
| EP0874829A1 (de) | 1998-11-04 |
| DE19536891A1 (de) | 1997-04-10 |
| CO4770961A1 (es) | 1999-04-30 |
| NZ319595A (en) | 2001-03-30 |
| HUP9900085A2 (hu) | 1999-04-28 |
| MX9801987A (es) | 1998-08-30 |
| MY115211A (en) | 2003-04-30 |
| AU7214796A (en) | 1997-04-28 |
| CA2231500A1 (en) | 1997-04-10 |
| BR9610821A (pt) | 1999-07-13 |
| SK43098A3 (en) | 1998-11-04 |
| NO981522D0 (no) | 1998-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981522L (no) | Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister | |
| DK0911340T3 (da) | Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel | |
| DK0832082T3 (da) | N-heteroaryl-pyridinsulfonamidderivater og deres anvendelse som endotelinantagonister | |
| NO991815L (no) | Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter | |
| DK0832104T3 (da) | Dolastatinderivater, deres fremstilling og anvendelse | |
| NO20006029L (no) | Pyrazolinderivater, deres fremstilling og anvendelse som legemidler | |
| DK1006110T3 (da) | Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler | |
| DK1019358T4 (da) | 3,3-diarylpropylaminer, deres anvendelse og fremstilling | |
| NO975513L (no) | 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel | |
| NO20005146D0 (no) | Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter | |
| NO991079L (no) | Azinyloksy- og fenoksy-diaryl-karboksylsyre-derivater, deres fremstilling og deres anvendelse som blandede ETA/ETB-endotelin-reseptor-antagonister | |
| DK0770059T3 (da) | Substituerede benzamidiner, deres fremstilling og deres anvendelse som lægemidler | |
| NO996115L (no) | Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister | |
| DK0931081T3 (da) | Pyridazino-[4,5-B]-quinolin-5-oxid-derivater, deres fremstilling og deres anvendelse som glycinantagonister | |
| NO995513L (no) | N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK- | |
| DK0839146T3 (da) | Piperazinderivater og deres anvendelse som 5-HT1A-antagonister | |
| NO951418D0 (no) | Peptidderivater, deres fremstilling og anvendelse som terapeutika | |
| NO20001934D0 (no) | 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse | |
| NO992976D0 (no) | Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister | |
| NO20000066D0 (no) | 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse | |
| DK619989A (da) | Dipeptidderivater, deres fremstilling og anvendelse som laegemidler | |
| NO20004075D0 (no) | Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister | |
| NO981002D0 (no) | Karboksylsyrederivater, deres fremstilling og anvendelse | |
| NO996244D0 (no) | Pyrrolidinkarboksylsyrederivater som endotelinantagonister | |
| DK1235809T3 (da) | Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MARCH 2003 |